Pamiparib is effective against both platinum-sensitive
and platinum-resistant ovarian cancer.
 |
| Image: Ovarian Cancer | InStyleHealth |
According to the findings of a phase II trial, the
selective oral PARP1/2 inhibitor Pamiparib is well tolerated and has good antitumor
activity with long-term responses in patients with platinum-sensitive ovarian
cancer (PSOC) or platinum-resistant ovarian cancer (PROC) with the germline
BRCA mutation (gBRCAmut).
The trial included 113 adult patients with PSOC (n=90;
disease progression occurred within 6 months of last platinum treatment) or
PROC (n=23; disease progression occurred within 6 months of last platinum
treatment) who were treated in China. These individuals had previously received
at least two lines of treatment and had a detrimental gBRCAmut.
Pamiparib 60 mg orally twice a day was given to all
patients until illness progression, toxicity, or patient withdrawal. The
primary outcome was the objective response rate (ORR) as determined by an
independent review committee (IRC) in accordance with RECIST version 1.1.
The population's median age was 54, and 25.6 percent
of patients had previously had four or more lines of systemic chemotherapy.
Approximately 86.7 percent of patients had a gBRCA1 mutation, whereas 13.3
percent had a gBRCA2 mutation. The majority of the patients (95.6%) had serous
epithelial tumors.
82 patients with PSOC and 19 patients with PROC were
examined for therapy efficacy over a median trial follow-up of 12.2 months. The
ORR for the PSOC group was 64.6 percent (95 percent confidence interval [CI],
53.3–74.9), with eight patients achieving a complete response (CR) and 45 achieving
a partial response (PR).
Six patients in the PROC group, on the other hand, had
a PR, resulting in an ORR of 31.6 percent (95 percent CI, 12.6–56.6).
Hematologic toxicities, such as anemia and a reduction
in neutrophil count, were often reported grade 3 adverse events.